NCT00349206View on ClinicalTrials.gov

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
MelanomaRecurrent MelanomaStage III MelanomaStage IV Melanoma
Interventions
DRUG

sorafenib tosylate

Given orally

DRUG

temsirolimus

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00349206 - Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | Biotech Hunter | Biotech Hunter